Organovo Data Presented At Digestive Disease Week (DDW2024) Demonstrating Potential For FXR314 As Combination Therapy With Tofacitinib For Inflammator...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel